Adaptive Pharmacogenomics, LLC

AMG 386 Treatment Response Increased With Dose And Exposure AMG 386 Moving Into Phase 3 For Recurrent Ovarian Cancer Separately, Two Analyses Provide Evidence Of Biomarker As Predictor Of Tumor Response To Motesanib THOUSAND OAKS, Calif., June 6, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer.  The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting. (Abstract Number: 5000)